P. Fasching

TROFUSE-011: a phase 3, randomized, open-label study of sacituzumab tirumotecan with or without pembrolizumab versus treatment of the physician’s choice for previously untreated, locally recurrent, unresectable, or metastatic triple-negative breast cancer with PD-L1 CPS<10

Introduction: The standard first-line therapy for most previously untreated, locally recurrent, unresectable, or metastatic triple-negative breast cancer (TNBC) with programmed death-ligand 1 (PD-L1) combined positive score (CPS)<10 is chemotherapy alone. New therapeutic options with superior efficacy are needed. Sacit...